ICER to consider broad outcomes for buprenorphines
In a draft scoping document published Thursday, ICER said it will consider a broad set of outcomes in its review of three buprenorphine products as medication-assisted treatments for opioid use disorder.
ICER is poised to review two recently marketed buprenorphine products -- the once-monthly injectable Sublocade from Indivior plc (LSE:INDV) and the implant Probuphine from Titan Pharmaceuticals Inc. (NASDAQ:TTNP) and Braeburn Pharmaceuticals Inc. (Princeton, N.J.) -- as well as Braeburn's extended-release injection CAM2038, which is under FDA review. The institute will compare the clinical effectiveness and value of the three products against drugs such as Suboxone buprenorphine/naltrexone sublingual film, injectable Vivitrol naltrexone and methadone (see BioCentury Extra, April 5). ...